EUVIMEDEUVIMED entdecken
Open Access

Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation

Steven S Carey iD, Jie Huang, Jason R Myers, Roya Mostafavi, Brent A Orr, Sandeep Kumar Dhanda, Layna H Michalik, Ruth G Tatevossian, Paul Klimo, Frederick Boop, Congyu Lu, Edgar Sioson und 8 weitere

Pediatric Blood & Cancer · 2024-10 · 71 (10)

DOI: 10.1002/pbc.31208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 21.07.2024. Verfasst von Steven S Carey und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospitalist Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Rhabdoid Tumor, Neoplasm Recurrence, Local, Teratoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, American Lebanese Syrian Associated Charities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survival data for recurrent pediatric atypical teratoid rhabdoid tumor (ATRT) and its association to molecular groups are extremely limited.

Methods

Single‐institution retrospective study of 64 children less than 21 years old with recurrent or treatment‐refractory (progressive disease [PD]) ATRT treated at St. Jude Hospital from January 2000 to December 2020. Demographic, clinicopathologic, treatment, molecular grouping (SHH, TYR, and MYC) and germline data were collected. Progression‐free survival (PFS2: time from PD to subsequent first progression) and overall survival (OSpostPD: time from PD to death/last follow‐up) were estimated by Kaplan–Meier analysis.

Results

Median age at and time from initial diagnosis to PD were 2.1 years (range: 0.5–17.9 years) and 5.4 months (range: 0.5–125.6 months), respectively. Only five of 64 children (7.8%) are alive at median follow‐up of 10.9 (range: 4.2–18.1) years from PD. The 2/5‐year PFS2 and OSpostPD were 3.1% (±1.8%)/1.6% (±1.1%) and 20.3% (±4.8%)/7.3% (±3.5%), respectively. Children with TYR group ( n = 10) had a better OSpostPD compared to those with MYC ( n = 11) (2‐year survival estimates: 60.0% ± 14.3% vs. 18.2% ± 9.5%; p = .019), or those with SHH ( n = 21; 4.8% ± 3.3%; p = .014). In univariate analyses, OSpostPD was better with older age at diagnosis ( p = .037), female gender ( p = .008), and metastatic site of PD compared to local or combined sites of PD ( p < .001). Two‐year OSpostPD for patients receiving any salvage therapy ( n = 39) post PD was 33.3% ± 7.3%.

Conclusions

Children with recurrent/refractory ATRT have dismal outcomes. Older age at diagnosis, female gender, TYR group, and metastatic site of PD were associated with relatively longer survival in our study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhabdoid TumorNeoplasm Recurrence, LocalTeratomaHumansMaleFemaleChildChild, PreschoolRetrospective StudiesInfantAdolescentSurvival RateFollow-Up StudiesPrognosisInfant, NewbornBiomarkers, Tumor

Stichwörter der Autor:innen

ATRT germline variantsATRT molecular groupsATRT survivalrecurrent ATRT

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hospitalist Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Genetics, Le Bonheur Children's Hospital, Memphis, Tennessee, USA.
  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Steven S Carey, Kim E Nichols, Thomas E Merchant, Amar Gajjar

Förderung

  • NCI NIH HHS
  • NIH HHS
  • American Lebanese Syrian Associated Charities
  • National Institutes of Health

Zitieren

APA

Carey, S. S., Huang, J., Myers, J. R., Mostafavi, R., Orr, B. A., Dhanda, S. K., Michalik, L. H., Tatevossian, R. G., Klimo, P., Boop, F., Lu, C., Sioson, E., Zhou, X., Nichols, K. E., Merchant, T. E., Ellison, D. W., Robinson, G. W., Onar-Thomas, A., Gajjar, A., & Upadhyaya, S. A. (2024). Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation. Pediatric Blood & Cancer, 71(10). https://doi.org/10.1002/pbc.31208

Vancouver

Carey SS, Huang J, Myers JR, Mostafavi R, Orr BA, Dhanda SK, et al. Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation. Pediatric Blood & Cancer. 2024;71(10). doi:10.1002/pbc.31208

BibTeX
@article{Carey2024,
  author = {Carey, Steven S and Huang, Jie and Myers, Jason R and Mostafavi, Roya and Orr, Brent A and Dhanda, Sandeep Kumar and Michalik, Layna H and Tatevossian, Ruth G and Klimo, Paul and Boop, Frederick and Lu, Congyu and Sioson, Edgar and Zhou, Xin and Nichols, Kim E and Merchant, Thomas E and Ellison, David W and Robinson, Giles W and Onar-Thomas, Arzu and Gajjar, Amar and Upadhyaya, Santhosh A},
  title = {Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {10},
  doi = {10.1002/pbc.31208}
}
Kostenlos starten →